Effect Of A Treatment Optimization Program To Improve Satisfaction With Viagra

Back to Search
Print
Bookmark Trial

NCT00159848

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Impotence
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male subjects above age of majority for whom sildenafil is prescribed for the first time within the usual practice of medicine

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Male subjects who have used any ED medical treatments over the last month, with the
exception of testosterone and/or herbal therapies


- Subjects who do not have the possibility of viewing the video either through a
computer, VCR or a DVD

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

ImpotenceEvaluation of the Index of Sexual Life Questionnaire NCT00245596
  1. Amphion-Les-Bains,
  2. Bordeaux,
  3. La Rochelle,
  4. Lille,
  5. Lyon Cedex 03,
  6. Lyon,
  7. PARIS Cedex 13,
  8. Paris,
  9. Saint-Emilion,
  10. Thionville,
  11. Toulouse,
Male
18 Years+
years
MULTIPLE SITES
ImpotenceAssessment Of Duration Of Action, Safety & Toleration Of UK369,003 and Cialis In Patients With Erectile Dysfunction NCT00174486
Male
18 Years+
years
MULTIPLE SITES
ImpotenceA Randomized Double Blind, Placebo Controlled Balanced 4-Way Crossover Study To Assess The Efficacy Of Single Oral Doses NCT00273416
  1. Oslo,
  2. Belfast, Northern Ireland
Male
18 Years+
years
MULTIPLE SITES
ImpotenceAssessment of Onset, Safety & Toleration of UK-369,003 in Male Erectile Dysfunction NCT00141349
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Birmingham, Alabama
  4. Mesa, Arizona
  5. Mesa, Arizona
  6. Mesa, Arizona
  7. Tempe, Arizona
  8. Beverly Hills, California
  9. San Bernardino, California
  10. Torrance, California
  11. Waterbury, Connecticut
  12. Aventura, Florida
  13. Pembroke Pines, Florida
  14. St. Petersburg, Florida
  15. West Palm Beach, Florida
  16. Evansville, Indiana
  17. Fort Wayne, Indiana
  18. Jeffersonville, Indiana
  19. Metairie, Louisiana
  20. Metairie, Louisiana
  21. Milford, Massachusetts
  22. Kansas City, Missouri
  23. New Brunswick, New Jersey
  24. Albany, New York
  25. Endwell, New York
  26. New York, New York
  27. Raleigh, North Carolina
  28. Raleigh, North Carolina
  29. Winston-Salem, North Carolina
  30. Beachwood, Ohio
  31. Cincinnati, Ohio
  32. Cleveland, Ohio
  33. Bryan, Texas
  34. Sugar Land, Texas
  35. Salt Lake City, Utah
  36. West Jordan, Utah
  37. Norfolk, Virginia
  38. Richmond, Virginia
  39. Milwaukee, Wisconsin
Male
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Effect Of A Treatment Optimization Program To Improve Satisfaction With Viagra
Official Title  ICMJE Effectiveness Of An Educational Program To Improve Patients' Satisfaction Regarding Their Management Of Erectile Dysfunction With Sildenafil
Brief Summary This study will demonstrate if a treatment optimization program has an impact on the satisfaction with Viagra treatment in men with erectile dysfunction
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Condition  ICMJE Impotence
Intervention  ICMJE Behavioral: Treatment Optimization Program (educational material)
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: September 8, 2005)		8000
Original Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE September 2003
Actual Primary Completion Date September 2003   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male subjects above age of majority for whom sildenafil is prescribed for the first time within the usual practice of medicine

Exclusion Criteria:

  • Male subjects who have used any ED medical treatments over the last month, with the exception of testosterone and/or herbal therapies
  • Subjects who do not have the possibility of viewing the video either through a computer, VCR or a DVD
Sex/Gender  ICMJE
Sexes Eligible for Study:Male
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00159848
Other Study ID Numbers  ICMJE NRA1481115
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP